Rainmed Medical Limited
潤邁德醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2297)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

FINANCIAL HIGHLIGHTS

	Unaudited Six months ended June 30,		
	2026	**2025**	Change
	***RMB million* (Except percentage)**	*RMB million* (Except percentage)	
Revenue	**14.7**	10.4	41.3%
Gross profit	**9.3**	5.1	82.4%
Gross profit margin	**63.2%**	49.2%	
Loss attributable to shareholders of the Company	**(22.0)**	(32.2)	-31.7%
Adjusted non-HKFRS loss attributable to shareholders of the Company[Note]	**(22.0)**	(33.8)	-34.9%
	RMB	*RMB*	
Loss per share – Basic and diluted	**(0.02)**	(0.03)	-33.3%
Adjusted non-HKFRS loss per share – Basic and diluted	**(0.02)**	(0.03)	-33.3%

The Board resolved not to declare any interim dividend for the six months ended June 30, 2026.

Note: For the six months ended June 30, 2026, the Group incurred loss of RMB22.0 million, including loss attributable to shareholders of the Company of RMB22.0 million, which was mainly attributable to ongoing expenses of research and development, manufacturing and commercialisation of medical instrument. Share-based payment expenses are non-cash expenses arising from Pre-IPO Share Option Scheme granted to certain management personnel and employees, which are commonly not included in similar non-HKFRS measures adopted by other companies in our industry. After eliminating potential impacts of certain non-cash or other expenses that do not affect our ongoing operating performance, including share-based payment expenses, the Group's adjusted non-HKFRS loss attributable to shareholders of the Company was RMB22.0 million.

The Board of Directors of the Company is pleased to announce that, the unaudited interim condensed consolidated results of the Group for the Reporting Period, together with the comparative figures of the same period of last year are set out below:

UNAUDITED INTERIM CONDENSED CONSOLIDATED INCOME STATEMENT

		Six months ended June 30,	
	Notes	**2026**	2025
		RMB'000	*RMB'000*
		(Unaudited)	(Unaudited)
Revenue	4	**14,672**	10,405
Cost of sales	5	**(5,394)**	(5,288)
Gross profit		**9,278**	5,117
Research and development expenses	5	**(4,921)**	(6,362)
Selling expenses	5	**(11,309)**	(15,090)
General and administrative expenses	5	**(16,820)**	(20,644)
Net impairment losses on financial assets		**(335)**	(76)
Other income		**47**	1,022
Other gains – net		**1,434**	2,795
Operating loss		**(22,626)**	(33,238)
Finance income		**133**	393
Finance costs		**(514)**	(437)
Finance income – net		**(381)**	(44)
Loss before income tax		**(23,007)**	(33,282)
Income tax expense	6	**–**	(9)
Loss for the period		**(23,007)**	(33,291)
Loss attributable to:			
Shareholders of the Company		**(21,989)**	(32,169)
Non-controlling interests		**(1,018)**	(1,122)
		(23,007)	(33,291)
Loss per share for the period attributable to the shareholders of the Company			
– Basic and diluted loss per share (RMB)	7	**(0.02)**	(0.03)

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss for the period	**(23,007)**	(33,291)
Other comprehensive (expense) income:		
Item that will not be reclassified to profit or loss		
Exchange differences arising from translation of the Company	**(16,673)**	(6,407)
Item that may be reclassified to profit or loss		
Exchange differences arising from translation of subsidiaries of the Company	**11,593**	3,818
Other comprehensive expense for the period, net of tax	**(5,080)**	(2,589)
Total comprehensive expense for the period	**(28,087)**	(35,880)
Total comprehensive expense attributable to:		
Shareholders of the Company	**(27,069)**	(34,758)
Non-controlling interests	**(1,018)**	(1,122)
	(28,087)	(35,880)

UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEET

	Notes	As at June 30, 2026 RMB'000 (Unaudited)	As at December 31, 2025 RMB'000 (Audited)
ASSETS			
Non-current assets			
Property, plant and equipment		**314,218**	275,824
Right-of-use assets		**5,040**	5,854
Intangible assets		**26,741**	32,035
Goodwill		**–**	–
Deferred income tax assets		**24,630**	24,630
Other receivables	8	**18**	36
		370,647	338,379
Current assets			
Inventories		**16,071**	11,354
Trade and other receivables	8	**49,911**	40,181
Prepayments		**3,089**	2,305
Financial assets at fair value through profit or loss ("**FVTPL**")		**121,258**	138,876
Cash and cash equivalents		**7,779**	14,405
		198,108	207,121
Total assets		**568,755**	545,500
EQUITY			
Share capital and share premium		**2,819,442**	2,819,442
Accumulated losses		**(2,547,955)**	(2,525,966)
Other reserves		**58,835**	63,915
Equity attributable to the shareholders of the Company		**330,322**	357,391
Non-controlling interests		**(423)**	595
Total equity		**329,899**	357,986

UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEET (CONTINUED)

	Notes	As at June 30, 2026 RMB'000 (Unaudited)	As at December 31, 2025 RMB'000 (Audited)
LIABILITIES			
Non-current liabilities			
Borrowings		**157,260**	4,000
Lease liabilities		**33**	84
Deferred income tax liabilities		**195**	195
		157,488	4,279
Current liabilities			
Borrowings		**23,790**	19,693
Trade and other payables	10	**42,660**	152,924
Contract liabilities	4	**14,031**	9,572
Current income tax liabilities		**–**	4
Lease liabilities		**887**	1,042
		81,368	183,235
Total liabilities		**238,856**	187,514
Total equity and liabilities		**568,755**	545,500
Net current assets		**116,740**	23,886

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

For the six months ended June 30, 2026

1. General Information

The Company was incorporated in the Cayman Islands on April 9, 2021 as a company with limited liability under the Companies Law, Cap. 22 of the Cayman Islands. The address of its registered office is Campbells Corporate Services Limited, Floor 4, Willow House, Cricket Square, Grand Cayman KY1-9010, Cayman Islands. The address of its principal place of business is Room 19-108, 19/F, Cityplaza Three, 14 Taikoo Wan Road, Taikoo, Hong Kong.

The Company is an investment holding company. The Company and its subsidiaries are primarily engaged in R&D, manufacturing and commercialisation of medical instrument related to caFFR System, caIMR System and IVD products in the PRC, Europe and other regions.

The Company's shares have been listed on the main board of the Stock Exchange since July 8, 2022.

These unaudited interim condensed consolidated financial information are presented in RMB, unless otherwise stated, which has been approved for issue on August 31, 2026.

2. Basis of preparation

This interim condensed consolidated financial information for the six months ended June 30, 2026 (the "**Interim Financial Information**") has been prepared in accordance with Hong Kong Accounting Standard ("**HKAS**") 34 "Interim Financial Reporting" issued by the Hong Kong Institute of Certified Public Accountants ("**HKICPA**"). The unaudited interim condensed consolidated financial information should be read in conjunction with the annual audited financial statements of the Company for the year ended December 31, 2025 which have been prepared in accordance with the HKFRS Accounting Standards issued by the HKICPA as set out in the accountant's report of the 2025 annual report of the Company dated March 31, 2026.

3. Accounting policies

The interim condensed consolidated financial information has been prepared under historical cost convention as modified by the revaluation of financial assets at FVTPL, which are carried at fair value. The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those presented in the consolidated financial statements of the Company for the years ended December 31, 2025, which have been prepared in accordance with the HKFRS Accounting Standards issued by the HKICPA, as set out in the 2025 Financial Statements, except as described below:

Application of amendments to HKFRS Accounting Standards

In the current interim period, the Group has applied, for the first time, the following amendments to HKFRS Accounting Standards issued by the HKICPA which are effective for the Group's financial year beginning January 1, 2026:

Amendments to HKFRS 9 and HKFRS 7	Amendments to the Classification and Measurement of Financial Instruments
Amendments to HKFRS 9 and HKFRS 7	Contracts Referencing Nature-dependent Electricity
Amendments to HKFRS Accounting Standards	Annual Improvements to HKFRS Accounting Standards – Volume 11

Impacts on application of Amendments to HKFRS 9 and HKFRS 7 Amendments to the Classification and Measurement of Financial Instruments

The amendments clarify the requirements for recognition and derecognition of financial assets and financial liabilities. In particular, a financial liability is derecognised on the "settlement date" and an accounting policy choice is introduced to derecognise financial liabilities settled using an electronic payment system before the settlement date, if specific conditions are met. The amendments include additional guidance on how the contractual cash flows for financial assets with environmental, social and corporate governance (ESG) and similar features should be assessed. Furthermore, the description of the term "non-recourse" is enhanced and the characteristics of "contractually linked instruments" are clarified in the amendments. The amendments specify new or amended disclosure requirements relating to investments in equity instruments designated at fair value through other comprehensive income and financial instruments with contingent features.

The application of the amendments in the current period had no material impact on these condensed consolidated financial statements.

Except as disclosed above, the application of the amendments to HKFRS Accounting Standards in the current interim period has had no material impact on the Group's financial performance and positions for the current and prior periods and/or on the disclosures set out in the interim condensed consolidated financial information.

4. Segment and revenue information

(a) Description of segments and principal activities

The Group is engaged in the R&D, manufacturing and commercialisation of medical instrument related to caFFR System, caIMR System and IVD products. For management purposes, the Group is not organised into business units based on their products and only has one reportable operating segment. Management monitors the operating results of the Group's operating segment as a whole for the purpose of making decisions about resource allocation and performance assessment.

(b) The amount of each category of revenue is as follows:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Timing of revenue recognition		
At a point in time:		
– Sales of products	**14,617**	9,774
Over time:		
– Installation and training services	**55**	631
	14,672	10,405

(c) The following table presents the analysis of contract liabilities related to the above-mentioned revenues:

	As at June 30, 2026	As at December 31, 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Contract liabilities:		
– Consideration for sales of goods	**11,945**	7,464
– Consideration for installation and training services	**2,086**	2,108
	14,031	9,572

Contract liabilities of the Group mainly arise from the advance payments made by customers while the underlying products or services are yet to be delivered or provided.

(d) Revenue recognised in relation to contract liabilities

The following table shows how much of the revenue recognised in the current reporting period relates to carried forward contract liabilities:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue recognised that was included in the balance of contract liabilities at the beginning of the period:		
– Sales of goods	**2,417**	641
– Installation and training services	**43**	16
	2,460	657

(e) Geographical information

Revenue from customers by geographic location as determined by destination of delivery is as follows:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	Revenue	Revenue
	(Unaudited)	(Unaudited)
China	**14,499**	9,461
Others	**173**	944
	14,672	10,405

As at June 30, 2026 and December 31, 2025, all of the non-current assets of the Group were located in the PRC.

(f) Information about major customers

The major customers which contributed more than 10% of the total revenue of the Group for the six months ended June 30, 2026 and 2025 are listed as below:

	Six months ended June 30,	
	2026	2025
	(Unaudited)	(Unaudited)
Customer A	*	12.63%
Customer B	*	11.91%
Customer C	**57.28%**	*
Total	**57.28%**	24.54%

* This customer contributed less than 10% of total revenue for the corresponding period.

5. Expenses by nature

Expenses included in cost of sales, R&D expenses, selling expenses and general and administrative expenses were analysed as follow:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Employee benefit expenses	**22,989**	26,604
Professional services	**1,783**	1,406
Depreciation and amortisation charges	**8,877**	10,619
Raw material costs	**739**	2,768
Changes in inventories of finished goods and work in progress	**(1,417)**	(765)
Travelling expenses	**1,322**	2,158
Promotion and hospitality expenses	**576**	2,153
Short-term lease expenses	**465**	238
Clinical trials and testing expenses	**–**	–
Utilities	**381**	262
Auditor's remuneration	**235**	310
Tax surcharges	**560**	286
Other expenses	**1,934**	1,345
	38,444	47,384

6. Income tax expense

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Income tax		
Current income tax charge	**–**	(9)

The Group's principal applicable taxes and tax rates are as follows:

(a) The Cayman Islands and the British Virgin Islands

The Company is incorporated in the Cayman Islands as an exempted company and is not liable for taxation in the Cayman Islands. The Group's subsidiary incorporated in the BVI is also an exempted company and is not liable for taxation in the BVI.

(b) Hong Kong

Subsidiary incorporated in Hong Kong is subject to Hong Kong profits tax at a rate of 16.5%. No provision for Hong Kong profits tax has been made as the Group did not have estimated assessable profit in Hong Kong during the six months ended June 30, 2026 and 2025.

(c) Mainland China

Pursuant to the Enterprise Income Tax Law of the PRC (the "**EIT Law**") and the Implementation Rules of the EIT Law, the EIT is unified at 25% for all types of entities, effective from January 1, 2008. No provision for PRC EIT has been made for the six months ended June 30, 2026 (for the six months ended June 30, 2025: RMB9,000), as the Group has no assessable profits arising in the PRC.

Suzhou Rainmed Medical Technology Company Limited ("**Suzhou Rainmed**"), the Group's major operating subsidiary in the PRC, has obtained the approvals to become a new and high-technology enterprise in December 2024 and December 2021, which is effective for three years commencing on January 1, 2024 and January 1, 2021. Suzhou Rainmed are entitled to a preferential income tax rate of 15% on the estimated assessable profits for the six months ended June 30, 2026 and 2025.

According to the PRC income tax law and its relevant regulations issued in 2023, entities that qualified as small and low profit enterprises with assessable profits not over RMB3,000,000 are effectively taxable at 5% (i.e. 20% corporate income tax rate on the 25% of the assessable profits) for the six months ended June 30, 2026 and 2025. Other group entities, which are not qualified as small-scale enterprises, operating in Mainland China are taxed at 25%. During the six months ended June 30, 2026, four (for the six months ended June 30, 2025: four) of the PRC subsidiaries of the Group qualified as small and low profit enterprises and are entitled to the preferential income tax rate of 5%.

According to the relevant laws and regulations promulgated by the State Administration of Taxation of the PRC that has been effective from 2021 onwards, enterprises engaging in research and development activities are entitled to claim 200% of their eligible research and development expenses so incurred as tax deductible expenses when determining their assessable profits for that year.

7. Loss per share

(a) Basic loss per share

Basic loss per share is calculated by dividing the loss of the Group attributable to shareholders of the Company by weighted average number of ordinary shares outstanding during the period.

In the calculation of weighted average number of ordinary shares outstanding for the six months ended June 30, 2026 and 2025, the shares issued to existing shareholders before public offering through the Capitalisation Issue had been adjusted retrospectively as if those shares have been issued since January 1, 2022. Basic loss per share is calculated by dividing the loss attributable to shareholders of the Company by the weighted average number of ordinary shares outstanding.

	Six months ended June 30,	
	2026	2025
	(Unaudited)	(Unaudited)
Loss attributable to shareholders of the Company (RMB'000)	**(21,989)**	(32,169)
Weighted average number of ordinary shares in issue ('000)	**1,291,938**	1,180,703
Basic loss per share (in RMB/share)	**(0.02)**	(0.03)

(b) Diluted loss per share

The Group has potential dilutive shares related to the Pre-initial public offerings ("**IPO**") share option scheme. For the six months ended June 30, 2026 and 2025 respectively, the potential ordinary shares were not included in the calculation of diluted loss per share as their inclusion would be anti-dilutive. Accordingly, diluted loss per share for the six months ended June 30, 2026 and 2025 are the same as basic loss per share.

8. Trade and other receivables

	As at June 30, 2026 RMB'000 (Unaudited)	As at December 31, 2025 RMB'000 (Audited)
Trade receivables (a)	**985**	1,307
Other receivables (b)	**48,944**	38,910
Less: non-current portion	**(18)**	(36)
Trade and other receivables in current portion	**49,911**	40,181

(a) Trade receivables

	As at June 30, 2026 RMB'000 (Unaudited)	As at December 31, 2025 RMB'000 (Audited)
Trade receivables	**1,408**	1,390
Less: provision for impairment	**(423)**	(83)
Trade receivables – net	**985**	1,307

The credit period for trade receivables was generally 60 to 180 days from the date of billing during the period. The ageing analysis of trade receivables based on invoice dates was as follows:

	As at June 30, 2026 RMB'000 (Unaudited)	As at December 31, 2025 RMB'000 (Audited)
Within 30 days	**454**	320
30 days to 90 days	**181**	281
91 days to 180 days	**50**	281
181 days to 365 days	**109**	206
1 year to 2 years	**614**	302
	1,408	1,390

(b) Other receivables

	As at June 30, 2026 ***RMB'000*** **(Unaudited)**	As at December 31, 2025 *RMB'000* (Audited)
Deposits	**19,285**	19,307
Value-added tax recoverable	**24,016**	14,025
Others	**5,706**	5,647
	49,007	38,979
Less: provision for impairment of other receivables	**(63)**	(69)
Other receivables – net	**48,944**	38,910
Less: non-current portion	**(18)**	(36)
	48,926	38,874

The maximum exposure to credit risk at the reporting date is the carrying amount of each class of receivables mentioned above.

The carrying amounts of the Group's other receivables approximate their fair values.

9. Dividend

No dividend has been paid or declared by the Company or the companies now comprising the Group during each of the six months ended June 30, 2026 and 2025.

10. Trade and other payables

	As at June 30, 2026 RMB'000 (Unaudited)	As at December 31, 2025 RMB'000 (Audited)
Trade payables	**2,716**	1,658
Staff salaries and welfare payables	**4,564**	4,914
Other tax payables	**5,883**	5,172
Payables for contractor and service supplier	**26,229**	137,364
Other accrued expenses	**3,268**	3,816
	42,660	152,924

The ageing analysis of trade payables based on invoice date are as follows:

	As at June 30, 2026 RMB'000 (Unaudited)	As at December 31, 2025 RMB'000 (Audited)
Within 1 year	**2,716**	1,658

Overview

Founded in 2014, we are committed to becoming a global leading vascular interventional surgical robotics company, with our current focus on the design, development and commercialization of caFFR System, caIMR System and IVD. Our Core Products, caFFR System and caIMR System, are innovative medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of CAD. They are designed to eliminate the usage of pressure wires, significantly reduce the risk of technical errors and operation time, and improve physiological assessment. These two systems are currently utilized singularly for precision diagnosis of CAD. As FFR measures the macrocirculation of arteries which account for 5% of all arteries and IMR measures the microcirculation of arteries which account for 95% of all arteries, therefore, using a combination of IMR and FFR can provide a comprehensive evaluation on coronary circulation status of CAD patients. In addition, our two systems were included into the Chinese Expert Consensus on Computation of Coronary Physiological Assessment Technology（《中國計算冠狀動脈生理學檢測技術專家共識》）in December 2022. The Expert Consensus fills the gap of the lack of guidance and norm in the clinical application of physiological indicators calculation in the intervention of coronary heart disease in China, and provides a basis for its standardized application and expansion of the scope of application. These two systems are also expected to form the center and crucial modules for our future vascular interventional surgical robots.

Our caFFR System has obtained both certificates of CE Mark in Europe and approvals from NMPA and several other countries. With the high accuracy rate of over 95% and convenient operation process that takes less than five minutes, our caFFR System has become a leading domestic FFR measurement product. We plan to expand the indication of our caFFR System from the current scope (covering patients with stable angina pectoris, unstable angina pectoris and post-acute phase of myocardial infarction) to further cover patients experiencing acute STEMI, acute NSTEMI and HFpEF. In addition, our caIMR System has obtained NMPA approval in April 2023, which is the only less-invasive IMR measurement product having completed a confirmatory clinical trial globally and becomes the first less-invasive IMR system approved for commercialization globally. Building on our caFFR System and caIMR System, combined with other related products of the Group, we aim to launch our vascular interventional surgical robot, that can be carried out for diagnostic and therapeutic purposes by connecting and integrating all our clinical applications, to automate the whole process of PCI.

Commercialization

During the first half of 2026 with a volatile market environment, we kept on expanding the market channels of our caFFR System, caIMR System and IVD in the industry, and have achieved steady results, which strengthen our competitive advantages in the FFR field and IMR field. Our revenue increased from RMB10.4 million for the six months ended June 30, 2025 to RMB14.7 million for the six months ended June 30, 2026, substantially all of which were generated from the sales of our FlashPressure caFFR pressure transducer, representing a year-on-year increase of approximately 41.3%.

We have a proven track record in commercializing our Core Products, caFFR System and caIMR System, with a comprehensive commercialization network in China, and we actively promote the commercialization network in the international market. We actively engage with KOLs – such as Dr. Ge Junbo and Dr. Huo Yong – physicians and medical associations as a part of our academic promotion and marketing strategy. As of June 30, 2026, our efficient and highly experienced sales team have established an extensive distribution network comprising 141 domestic distributors who are authorized by us to cover over 291 hospitals across 21 provinces, four autonomous regions and four municipal cities in China. With our effective and extensive sales and marketing activities, as of June 30, 2026, our Core Products had been sold to and installed in over 790 hospitals and had been performed at over 1,500 hospitals in China, and we had completed the procurement approval procedure with over 750 hospitals in China. We have also obtained the patient charging price of RMB10,200 to RMB12,000 for our proprietary consumable of caFFR System in 33 provinces and regions, among which 24 provinces and regions (such as Shanghai, Guangdong, Chongqing, Henan, etc.) included our proprietary consumable of caFFR System into the medical insurance reimbursement list. Currently, we are fully promoting the implementation of including our proprietary consumable of caIMR System into the medical insurance reimbursement list. In addition, the Group's coronary artery cutting balloon product began contributing to revenue during the Reporting Period. This product has been included in the national centralized bulk procurement scope for medical devices and is expected to further increase sales scale by leveraging the expanded market coverage and accelerated hospital access resulting from the centralized bulk procurement scope.

Research and Development

Our R&D team develops innovative products focusing on the field of interventional precision diagnosis and treatment. We have a dedicated in-house R&D team primarily based in Suzhou, Jiangsu province, China led by Mr. Liu Guangzhi, our chief technology officer, who has over ten years of experience in medical device development and over 19 years of experience in software and algorithm development as well as profound management experience.

Our four R&D platforms include the medical imaging algorithm and application R&D platform, the fluid dynamics simulating calculation platform, the high-performance device R&D platform and the interventional consumables R&D platform. These platforms adhere to inhouse development and innovation, capture market demand and actively explore various clinical applications for our products so as to timely upgrade our products and product candidates catering to the market demands. Our platform technologies complement each other and create a synergistic effect for our R&D efforts.

As of June 30, 2026, we had (i) 213 approved patents, including 186 approved in China, 7 approved in the U.S., 4 approved in Europe and 16 approved in Japan; (ii) 61 pending patent applications, including 61 in China; (iii) 341 registered trademarks; and (iv) 15 registered software copyrights.

Manufacturing

Our commercialization efforts are well supported by our growing manufacturing capability. As of June 30, 2026, we had three manufacturing sites, two of which were located in Suzhou, Jiangsu province, China, and one was located in Tianjin, China, with a production base area of approximately 7,962 sq.m.. Our manufacturing facilities are in compliance with the GMP for medical devices in China. It is expected to be able to produce 11,375 units of consoles as well as 1,130,765 units of pressure transducers (disposable consumables) and over 80 types of IVD products each year. The console and the single-use pressure transducer can be used for assembling our caFFR System and caIMR System. In addition, we acquired approximately 20,000 sq.m. of land in Suzhou, Jiangsu Province, China in May 2023 for the construction of our own manufacturing and R&D bases, which will integrate our existing manufacturing facilities and R&D facilities, enhance the overall strength of our Group and provide a convenient site for our future manufacturing pipelines.

Product and Pipeline

Products and Product Candidates[2]			Indication	Type	Stage				Upcoming Milestone	Expected Launch Date
					Preclinical	Clinical	Registration	Approval		
Vascular Interventional Diagnosis and Treatment Surgical Robot	Digital Functional Diagnostic Module	caFFR System (comprising the FlashAngio caFFR System and the FlashPressure caFFR pressure transducer)	Coronary Artery Disease	III	*China*			*NMPA Approval*	N/A	Launched
				III	*China*		*Post Registration clinical trialfor indication expansion* [1]		In progress	2026
				IIa	*Europe*	*CE Mark: exempted from clinical trial requirement*			N/A	Launched
				II	*South Korea*			*Korea's National Institute of Medical Device Safety Information Approval*	N/A	Launched
				II	*United States*				Discontinued	–
		caIMR System (comprising the FlashAngio caIMR System and the FlashPressure caIMR pressure transducer)	Coronary Artery Disease	III	*China*			*NMPA Approval*	N/A	Launched
				III	*China*		*Post Registration clinical trialfor indication expansion* [3]		Initiation of clinical trials	2029
				IIa	*Europe*[2]	*CE Mark: exempted from clinical trial requirement*			N/A	Launched
				II	*South Korea*			*Korea's National Institute of Medical Device Safety Information Approval*	N/A	Launched
				II	*United States*				Discontinued	–
		Intelligent Angiographic Injection System	Vascular Disease	III		*NMPA Approval: Exempted from clinical trial requirement*			Discontinued	–
	Automated Interventional Module	Flash Robot Vascular Intervention Navigation Operation System	Coronary Artery Disease	III					Discontinued	–
			Peripheral Vascular Disease	III					Discontinued	–
			Neurovascular Disease	III					Discontinued	–
		Flash RDN System	Hypertension	III					Discontinued	–

- Core Product
- This device is exempted from clinical trial requirements in accordance with the Catalogue of Medical Devices Exempted from Clinical Evaluation（《免於臨床評價醫療器械目錄》）promulgated by the NMPA.

Notes:

(1) Indication expansion of caFFR System includes acute STEMI, acute NSTEMI and HFpEF.

(2) We have global commercial rights for all of our products and product candidates.

(3) Indication expansion caIMR System includes STEMI immediately after successful revascularization of targeted vessels.

caFFR System

Our caFFR System is a less-invasive physiological assessment of coronary artery ischemia severity based on CAG images, and it is indicated for monitoring real-time aortic pressure in all stages of the cardiac cycle and assessing various physiological parameters for patients with stable angina pectoris, unstable angina pectoris and acute myocardial infarction (at least seven days after myocardial infarction). Our caFFR System is a Class III medical device under the classification criteria of the NMPA.

We commenced the confirmatory clinical trial for our caFFR System in March 2018 and completed such trial in May 2019. We obtained the CE Mark from the European Union in September 2019 and started to commercialize our caFFR System in overseas markets (such as the Czech Republic, France and Austria) in October 2019. In addition, we received the registration certificate of Class III medical device from the NMPA in December 2019 and began to commercialize our caFFR System in China in January 2020. Our R&D in relation to our caFFR System has been a continuing effort. We initiated a post-registration clinical trial in China in August 2020 to expand the indication of our caFFR System from its current scope to further cover patients experiencing acute STEMI, acute NSTEMI and HFpEF. We obtained Australian TGA certification in 2022, secured approval from Brazilian National Health Surveillance Agency for commercialization of our caFFR system in January 2024, and received approval from Korea Institute of Medical Device Safety Information Approval for commercialization of our caFFR system in June 2024.

caIMR System

We have currently completed our caIMR System and obtained NMPA approval. Our caIMR System is a Class III medical device under the classification criteria of the NMPA, and such system is the only less-invasive IMR measurement product having completed a confirmatory clinical trial globally and becomes the first less-invasive IMR system approved for commercialization globally. In May 2022, Dr. Ge Junbo, the president of the Cardiovascular Society of the Chinese Medical Doctor Association and the chief of the Department of Cardiology in the Zhongshan Hospital of Fudan University, published the confirmatory clinical research results of our caIMR System at the European Association of Percutaneous Cardiovascular Interventions, the world's top academic conference for cardiovascular intervention. Compared with wire-based IMR, the diagnostic performance of our caIMR System indicated a diagnostic accuracy of 93.8%, sensitivity of 95.1%, and specificity of 93.1%. We obtained NMPA, ANVISA and The Ministry of Health and Welfare of Korea (MOHW) approvals for commercialization of our caIMR System in April 2023, January 2024 and June 2024 respectively.

Flash Robot Vascular Intervention Navigation Operation System

Flash Robot Vascular Intervention Navigation Operation System is our proprietary robot-assisted platform designed for navigation and operation. We plan to provide a "one-stop hybrid procedure" that can be carried out for diagnostic and therapeutic purposes at the same time in the future. Robot-assisted operation enables precise measurement of anatomy and device positioning with the added benefit of radiation protection for the physicians. Consisting of a robotic arm and a control unit (including a console and a surgical image navigation system), our Flash Robot Vascular Intervention Navigation Operation System allows physicians to precisely guide a catheter through patient's blood vessels and further perform the operation. As of June 30, 2026, the Flash Robot Vascular Intervention Navigation Operation System was at its research improvement stage. In February 2022, our Flash Robot Vascular Intervention Navigation Operation System entered into the animal study stage and successfully passed the first animal sample trial.

IVD Products

Our IVD product business is in the field of biochemical in vitro diagnostic reagents. We currently have obtained 85 Class II registration certificates for biochemical diagnostic reagent products and corresponding production licenses, covering major diagnostic categories such as liver function, kidney function, blood lipids, and cardiac muscle, with a wide range of products. Currently, a series of innovative precision diagnostic products for cardiovascular IVD such as "coagulation" and "peptide" are under R&D, further improving the Group's product layout.

WE CANNOT GUARANTEE THE FUTURE PROSPECTS OF OUR CORE PRODUCTS, caFFR SYSTEM AND caIMR SYSTEM, AND WE MAY NOT BE ABLE TO SUCCESSFULLY DEVELOP AND/OR MARKET OUR OTHER CORE PRODUCTS OR ANY OTHER PRODUCT CANDIDATES.

Outlook and Prospect

Since the beginning of this year, the compliance of medical devices has become stricter and the market was full of uncertainties. We have made more arduous efforts than before, and still achieved considerable results. Our core product caIMR system successfully obtained the approvals for commercialization from the NMPA and the ANVISA, and we entered into the in vitro diagnostic field through the acquisition of Tianjin Yuehekang. Looking forward to the second half of the year, despite the challenging industry situation, we still need to strengthen the Company's competitive advantages in the field of FFR and IMR and other products, and further penetrate the market in Mainland China, with an effort to achieve healthy growth and high-quality development throughout 2026.

FINANCIAL REVIEW

Revenue

Substantially all of our revenue was generated from the sales of our caFFR System and caIMR System since their commercialization. We sold substantially all of our products through our distributors for the six months ended June 30, 2026 and 2025. Our contracts with distributors include a component of installing our devices and providing training services in addition to delivering products. We recognize revenue for sales of products upon delivery and recognize revenue for installation and training services after we have completed the relevant services. The following table sets forth a breakdown of our revenue by nature for the periods indicated:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Sales of products		
– Sales of FlashAngio caFFR System	**75**	66
– Sales of FlashPressure caFFR pressure transducer	**11,908**	6,781
– Sales of FlashAngio caIMR System	**112**	630
– Sales of IVD products	**1,134**	2,297
– Sales of coronary artery cutting balloon	**1,388**	–
Installation and training services	**55**	631
Total	**14,672**	10,405

Our revenue increased by approximately 41% from RMB10.4 million for the six months ended June 30, 2025 to RMB14.7 million for the six months ended June 30, 2026, primarily due to the increased sales of our FlashPressure caFFR pressure transducer. At the same time, the Group's coronary artery cutting balloon, as a type of product included in the centralized bulk procurement scope, began generating sales revenue of approximately RMB1.39 million during the Reporting Period. As the centralized procurement policy continues to be advanced and the number of covered hospitals gradually increases, sales volume of this product is expected to rise steadily.

Gross Profit and Gross Profit Margin

Our gross profit increased by approximately 82.4% from RMB5.1 million for the six months ended June 30, 2025 to RMB9.3 million for the six months ended June 30, 2026, primarily due to the increased sales of our FlashPressure caFFR pressure transducer. Our gross profit margin increased from 49.2% for the six months ended June 30, 2025 to 63.2% for the same period in 2026, primarily due to a significant increase in income and the control of costs.

Research and Development Expenses

During the Reporting Period, our R&D expenses primarily consisted of (i) employee benefit expenses, including salaries, bonus and fringe benefits for R&D team; (ii) raw material costs for our R&D activities; (iii) professional service expenses, mainly representing expenses incurred in relation to (a) our intellectual property rights, such as patent application fees and patent maintenance fees, and (b) our product registration applications; and (iv) depreciation and amortization charges. The following table sets forth a breakdown of our R&D expenses for the periods indicated:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Employee benefit expenses	**3,067**	4,635
Raw material costs	**1,044**	356
Professional service expenses	**180**	245
Depreciation and amortization charges	**282**	864
Other expenses	**348**	262
Total	**4,921**	6,362

Our R&D expenses decreased from RMB6.4 million for the six months ended June 30, 2025 to RMB4.9 million for the six months ended June 30, 2026, representing approximately 22.7% year-on-year decrease over the same period in 2025. Such decrease was primarily due to a decrease of RMB1.6 million in employee benefit expenses mainly as a result of the control of cost and expenses.

Selling Expenses

During the Reporting Period, our selling expenses primarily consisted of (i) employee benefit expenses, including salaries, bonus and fringe benefits for sales and marketing team; (ii) marketing development expenses, primarily including expenses in connection with our sales and marketing activities, such as conference costs, travel expenses, expenses incurred for exhibitions and expenses paid to third-party research institutes for conducting market researches; and (iii) depreciation and amortization charges. The following table sets forth a breakdown of our selling expenses for the periods indicated:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Employee benefit expenses	**8,963**	9,713
Marketing development expenses	**1,693**	5,126
Depreciation and amortization charges	**145**	193
Other expenses	**508**	58
Total	**11,309**	15,090

Our selling expenses decreased from RMB15.1 million for the six months ended June 30, 2025 to RMB11.3 million for the six months ended June 30, 2026, representing approximately 25.1% year-on-year decrease over the same period in 2025. Such decrease was primarily due to (i) a decrease of RMB3.4 million in marketing development expenses as a result of shrinking of sales and marketing activities; and (ii) a decrease of RMB0.8 million in employee benefit expenses mainly as a result of the control of cost and expenses.

General and Administrative Expenses

During the Reporting Period, our general and administrative expenses primarily consisted of (i) employee benefit expenses, including salaries, bonus and fringe benefits for administrative team; (ii) listing expenses; (iii) depreciation and amortization charges; and (iv) professional service expenses, which were primarily associated with corporate legal services. The following table sets forth a breakdown of our general and administrative expenses for the periods indicated:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Employee benefit expenses	**7,893**	10,754
Depreciation and amortization charges	**5,658**	6,086
Professional service expenses	**1,113**	1,156
Other expenses *Note*	**2,156**	2,648
Total	**16,820**	20,644

Note: Mainly included office expenses, entertainment expenses, travel expenses and property management fees.

Our general and administrative expenses decreased from RMB20.6 million for the six months ended June 30, 2025 to RMB16.8 million for the six months ended June 30, 2026, representing approximately 18.5% year-on-year decrease over the same period in 2025. Such decrease was primarily due to a decrease of RMB2.9 million in employee benefit expenses mainly in relation to a decrease in salaries and our administrative employee headcount.

Other Income

Our other income decreased from RMB1.0 million for the six months ended June 30, 2025 to RMB0.05 million for the six months ended June 30, 2026, primarily due to our receipt of one-off government grants in 2025.

Income Tax Expenses

Our income tax expense decreased from RMB0.01 million for the six months ended June 30, 2025 to RMB0 million for the six months ended June 30, 2026, primarily due to the profit generated from a subsidiary decreased as a result of interest income.

Loss for the Period

For the reasons described above, we recorded a loss of RMB23.0 million for the six months ended June 30, 2026, compared with a loss of RMB33.3 million for the six months ended June 30, 2025.

Liquidity and Financial Resources

Our primary uses of cash were to fund the development of our product candidates, our clinical trials, our payment for the purchase of plant and equipment, administrative expenses, selling expenses and other recurring expenses.

For the six months ended June 30, 2026, our net cash used in operating activities was RMB17.2 million, primarily because we incurred significant R&D expenses, administrative expenses and selling expenses during the Reporting Period. During the Reporting Period, we mainly relied on capital contribution from Shareholders and equity financing as the main source of liquidity. Our management closely monitors the utilisation of cash and cash balances and strives to maintain healthy liquidity for our business. Going forward, we believe that our liquidity requirements will be satisfied with the net proceeds from the Global Offering, our cash and cash equivalents on hand and cash generated from our operations.

For the six months ended June 30, 2026, our net cash generated from investing activities was RMB146.7 million, primarily attributable to the redemption of FVTPL investments amounting to RMB13.6 million, which was partially offset by the purchase of property, plant and equipment of RMB160.3 million.

For the six months ended June 30, 2026, our net cash generated from financing activities was RMB157.1 million, primarily attributable to proceeds from bank and other borrowings of RMB165.6 million.

As at June 30, 2026, our cash and cash equivalents amounted to RMB7.8 million, representing a decrease of RMB6.6 million from RMB14.4 million as at December 31, 2025. Our net current assets increased from RMB23.9 million as at December 31, 2025 to RMB116.7 million as at June 30, 2026, primarily attributable to the decrease in trade payables and other payables.

As at June 30, 2026, the Group's gearing ratio, which is calculated by interest-bearing borrowing less cash and cash equivalent divided by total equity, was 54.9%, as cash and cash equivalents were less than the Group's interest-bearing borrowings.

Indebtedness

As at June 30, 2026, our outstanding balance of borrowings was RMB181.1 million. We had unutilized bank facilities of RMB20.0 million.

Our lease liabilities decreased from RMB1.1 million as at December 31, 2025 to RMB0.9 million as at June 30, 2026, primarily attributable to lease payments.

Capital Commitments

As at June 30, 2026, we had capital commitments contracted but not provided for of RMB23.1 million in relation to the purchase of construction and service for the Group's industrial park.

Charges on Assets

As at June 30, 2026, the Group's bank borrowings are secured by the land use rights under the immovable property certificates held by the Group (for the six months ended June 30, 2025: nil).

Contingent Liabilities

As at June 30, 2026, we did not have any material contingent liabilities (for the six months ended June 30, 2025: nil).

Significant Investments, Material Acquisitions and Disposals

During the Reporting Period, we did not hold any significant investments nor conduct any material acquisitions and disposals of subsidiaries, associates or joint ventures.

Foreign Exchange Exposure

We are exposed to foreign currency risk primarily arising from cash at banks denominated in USD. We currently do not have a foreign currency hedging policy. However, our management monitors foreign exchange exposure and will consider appropriate hedging measures in the future should the need arise.

Future Plans for Material Investments or Capital Assets

The Group will continue to expand its markets in the PRC and globally in order to tap its internal potential and maximize Shareholders' interest. The Group will continue to push products development in our pipeline. The Group will continue to grow through self-development, mergers and acquisitions, and other means. We will employ a combination of financing channels to finance capital expenditures, including but not limit to internal funds and bank loans. Currently, the bank credit lines available to the Group are adequate.

Human Resources

As of June 30, 2026, the Group employed 208 full-time employees, most of whom were stationed in China. During the Reporting Period, the Group's total employee benefit expenses (including (i) wages, salaries and bonuses; (ii) social security costs; and (iii) employee benefits. We recruit our employees based on a number of factors, including their work experience, educational background and the requirements of the relevant vacancies. We invest in continuing education and training programmes for our management staff and other employees to continuously improve their skills and knowledge. We provide regular feedback to our employees, as well as internal and external training in various areas such as product knowledge, project development and team building. We also assess the performance of our employees to determine their salaries, promotion opportunities and career development. In accordance with the relevant PRC labour laws, we enter into individual employment contracts with our employees covering matters such as tenure, wages, bonuses, employee benefits, workplace safety, confidentiality obligations, non-competition and grounds for termination. In addition, we are required under PRC law to make contributions to statutory employee benefit plans (including pension plans, medical insurance, work-related injury insurance, unemployment insurance, maternity insurance and housing funds) at certain percentages of the salaries (including bonuses and allowances) of our employees, up to a maximum amount specified by the local government. The adoption of the Pre-IPO Share Option Scheme of 707,628 Shares (adjusted to 35,381,400 Shares after the Capitalisation Issue) was approved at the Board meeting of the Company held on December 10, 2021. The purpose of the Scheme is to attract, motivate and retain skilled and experienced personnel to strive for the future development and expansion of the Group. The Scheme also helps the Company to modernize its remuneration practices and improve the balance of interests among Shareholders, operation and execution management by aligning their interests.

INTERIM DIVIDEND

The Board does not recommend the payment of any interim dividend for the six months ended June 30, 2026 (for the six months ended June 30, 2025: nil).

SUBSEQUENT EVENTS AFTER THE REPORTING PERIOD

No significant events occurred since the end of the Reporting Period.

CORPORATE GOVERNANCE PRACTICES

The Group is committed to maintaining high standards of corporate governance to safeguard the interests of the Shareholders and to enhance corporate value and accountability. The Company has adopted the CG Code as set out in Appendix C1 to the Listing Rules.

For the six months ended June 30, 2026, the Company complied with all code provisions of the CG Code. The Company will continue to review and monitor its corporate governance practices to ensure compliance with the CG Code.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as set out in Appendix C3 to the Listing Rules as its own code of conduct regarding securities transactions by the Directors. Having made specific enquiry with the Directors, all Directors confirmed that they have complied with the standards set out in the Model Code for the six months ended June 30, 2026.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

For the six months ended June 30, 2026, neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares). As of June 30, 2026, the Company did not have treasury shares.

AUDIT COMMITTEE

The Board has established the Audit Committee, comprising three independent non-executive Directors, i.e., Mr. Liu Shuen Kong, Mr. Chen Xuefeng and Mr. Zhao Hui, with Mr. Liu Shuen Kong serving as the chairman. The primary duties of the Audit Committee are to assist the Board by providing an independent view of the effectiveness of the financial reporting process, internal control and risk management systems of our Group, overseeing the audit process, and performing other duties and responsibilities as assigned by the Board.

The Audit Committee, together with the management, has reviewed the condensed interim financial information of the Group for the six months ended June 30, 2026, which has not been reviewed by the Company's auditors. The Audit Committee has reviewed the accounting standards adopted by the Group and has discussed matters on audit, internal control, risk management and financial reporting.

PUBLICATION OF THE INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

This interim results announcement is published on the websites of the Stock Exchange (www. hkexnews.hk) and the Company (www.rainmed.com), and the 2026 interim report containing all the information required by the Listing Rules will be dispatched to the Shareholders and published on the respective websites of the Stock Exchange and the Company in due course.

DEFINITIONS

In this interim results announcement, the following expressions shall have the meanings set out below, unless the context otherwise requires:

"Audit Committee"	the audit committee of the Board
"Board of Directors" or "Board"	the board of Directors
"BVI"	the British Virgin Islands
"CAD"	coronary artery diseases, a condition where the major blood vessels supplying the heart are narrowed to reduce blood flow that can cause chest pain and shortness of breath
"caFFR"	coronary angiography-derived fractional flow reserve, a novel less-invasive index to determine the FFR in patients with stable or unstable angina
"CAG"	coronary angiography, a percutaneous procedure that uses contrast dye and X-ray images to detect coronary artery diseases
"caIMR"	coronary angiography-derived index of microvascular resistance, which is proposed for physiological assessment of microvascular diseases in coronary circulation
"CE Mark"	a certification mark that indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area
"CG Code"	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
"China" or "PRC"	the People's Republic of China, which for the purpose of this announcement and for geographical reference only, excludes Hong Kong, the Macau Special Administrative Region of the People's Republic of China and Taiwan
"Company" or "our Company"	Rainmed Medical Limited（潤邁德醫療有限公司）, an exempted company with limited liability incorporated in the Cayman Islands on April 9, 2021

"confirmatory clinical trial"	a controlled clinical trial of a medical device product designed to demonstrate statistically significant clinical efficacy and safety of such product as used in human patients (in conjunction with the implementation of a therapeutic procedure), for regulatory approval of such product
"Core Product"	has the meaning ascribed thereto in Chapter 18A of the Listing Rules, which, for the purpose of this announcement, refers to each of caFFR System and caIMR System
"Director(s)"	the director(s) of the Company
"FFR"	fractional flow reserve, a technique used in coronary catheterization to measure pressure differences across a coronary artery stenosis at maximal hyperemia to determine the likelihood that the stenosis impedes oxygen delivery to the heart muscle and diagnose myocardial ischemia
"Global Offering"	has the meaning as ascribed to it under the Prospectus
"GMP"	good manufacturing practice, the quality assurance that ensures that medical products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the product specification
"Group", "our Group", "we", "us" or "our"	our Company and its subsidiaries from time to time or, where the context so requires, in respect of the period prior to our Company becoming the holding company of its present subsidiaries, such subsidiaries as if they were subsidiaries of the Company at the relevant time
"HFpEF"	heart failure with preserved ejection fraction, a condition which occurs when the lower left chamber (left ventricle) is not able to fill properly with blood during the diastolic (filling) phase and the amount of blood pumped out to the body is less than normal
"HKFRS"	Hong Kong Financial Reporting Standards, as issued from time to time by the Hong Kong Accounting Standards Board
"Hong Kong dollars", "HKD" or "HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC

"IMR"	index of microcirculatory resistance, the quantitative assessment of the minimum microcirculatory resistance in a target coronary arteriolar territory
"IVD"	in vitro diagnostic
"KOL(s)"	key opinion leader(s), renowned physicians who are able to influence their peers' medical practice
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended, supplemented or otherwise modified from time to time)
"Listing"	the listing of the Shares on the Main Board of the Stock Exchange
"Main Board"	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with the GEM of the Stock Exchange
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules
"NMPA"	National Medical Products Administration of the PRC (國家藥品監督管理局), the successor to the China Food and Drug Administration (國家食品藥品監督管理總局)
"Nomination Committee"	the nomination committee of the Board
"NSTEMI"	non-ST segment elevation myocardial infarction, a heart attack that occurs without ST segment elevation on the electrocardiogram
"PCI"	percutaneous coronary intervention, a percutaneous procedure to open a narrowed or blocked coronary artery and restore arterial blood flow to heart tissue that does not involve open-chest surgery
"Pre-IPO Share Option Scheme"	the share option scheme adopted by our Company on December 10, 2021
"Prospectus"	the prospectus of the Company dated June 27, 2022 in relation to the Global Offering
"R&D"	research and development

"Remuneration Committee"	the remuneration committee of the Board
"Reporting Period"	the six months ended June 30, 2026
"RMB" or "Renminbi"	Renminbi, the lawful currency of the PRC
"Share(s)"	ordinary share(s) with a par value of HK$0.0001 each in the share capital of the Company
"Shareholder(s)"	holder(s) of the Share(s)
"sq.m."	square meter, a unit of area
"STEMI"	ST segment elevation myocardial infarction, which occurs due to occlusion of one or more coronary arteries, causing transmural myocardial ischemia
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary(ies)"	has the meaning ascribed thereto under the Listing Rules
"Suzhou Rainmed"	Suzhou Rainmed Medical Technology Co., Ltd. （蘇州潤邁德醫療科技有限公司）, a limited liability company incorporated under the laws of PRC on December 5, 2016, being a wholly owned subsidiary of our Company
"U.S. dollars", "US$" or "USD"	United States dollars, the lawful currency of the United States
"United States" or "U.S."	the United States of America, including its territories, possessions and all areas subject to its jurisdiction
"%"	per cent

By Order of the Board
Rainmed Medical Limited
Huo Yunfei
Chairman of the Board and Executive Director

Hong Kong, August 31, 2026

As at the date of this announcement, the Board comprises Mr. Huo Yunfei and Ms. Duan Jing as executive Directors, Dr. Huo Yunlong, Mr. Wang Lin and Mr. Heng Lei as non-executive Directors, and Mr. Liu Shuen Kong, Mr. Chen Xuefeng and Mr. Zhao Hui as independent non-executive Directors.